BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 1, 2004
View Archived Issues
New class of antiinflammatory agents by Wyeth
Read More
Potent peripherally restricted mu agonist for pain therapy
Read More
Studies suggest that botulinum A toxin is both effective and safe in bladder disorders
Read More
Studies reveal tolerability and efficacy of darifenacin in overactive bladder
Read More
Urgency reduced by solifenacin in overactive bladder patients
Read More
New data on tamsulosin presented at the 19th EAU congress
Read More
RO-3202904 may be better tolerated than other overactive bladder treatments
Read More
Studies find dutasteride effective in benign prostatic hyperplasia
Read More
Atrasentan delays disease progression in metastatic prostate cancer
Read More
Strontium-89, olpadronate reduce bone pain in metastatic prostate cancer
Read More
NAD-299, RS-23597 active in prostate cancer cells
Read More
NIAID to support development of Crucell's candidate malaria vaccine
Read More
Innogenetics acquires Genencor's therapeutic vaccine programs
Read More
Vernalis to reacquire North American rights to frovatriptan
Read More
Amgen to acquire Tularik
Read More
YM BioSciences to commence pivotal tesmilifene trial in coming weeks
Read More
QLT acquiring Kinetek
Read More
Second phase III study of RSD-1235 in atrial fibrillation commences
Read More
Quigley completes pre-IND meeting for QR-333
Read More
Phase II Psoraxine trial under way
Read More
Enrollment opens in phase III trial of STR in multiple myeloma
Read More
Exenatide LAR enters phase II study in patients with type 2 diabetes
Read More
Amylin PYY obesity drug candidate enters phase I safety study
Read More
Enrollment completed in phase II obesity study of AC-137
Read More
CV Therapeutics seeks European approval of ranolazine for chronic angina
Read More
Remune selected for new Canadian HIV trial
Read More
Enrollment completed in phase II study of Deltavasc for PAD
Read More
Corporate developments at Merck & Co.
Read More
Second phase III study for Oxytrex
Read More
Corixa licenses RC-529 adjuvant rights to Aventis
Read More
PARP inhibitors claimed in Kyorin patents
Read More
Takeda discloses novel series of beta-secretase inhibitors
Read More
Inhibitors of sodium-dependent glucose co-transporter emerge from Taisho research
Read More
Compounds for treatment of pneumovirus infections covered in ViroPharma patent
Read More
Bayer claims diagnostics and therapeutics for GPR19-associated diseases
Read More
Resorcinol derivatives for the treatment of diabetes claimed by Sankyo
Read More
Procter & Gamble patent covers new antimicrobial quinolones
Read More
Pladienolide D derivative, E-7107, shows good antitumor activity in xenografts
Read More
Promising MIF inhibitor for prophylaxis and treatment of type 1 diabetes
Read More
Congress presentations report PD-0332991's biochemical, pharmacological and pharmacokinetic profile
Read More